Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America

Cancer

Volumn 116, Issue 5, 2010, Pages 1272-1280

  Stadler, Walter M ^a   Figlin, Robert A ^b   McDermott, David F ^c   Dutcher, Janice P ^d   Knox, Jennifer J ^e   Miller Jr , Wilson H ^f   Hainsworth, John D ^g   Henderson, Charles A ^h   George, Jeffrey R ⁱ   Hajdenberg, Julio ^j   Kindwall Keller, Tamila L ^k   Ernstoff, Marc S ^l   Drabkin, Harry A ^m   Curti, Brendan D ⁿ   Chu, Luis ^o   Ryan, Christopher W ^p   Hotte, Sebastien J ^q   Xia, Chenghua ^r   Cupit, Lisa ^r   Bukowski, Ronald M ^s  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d NEW YORK MEDICAL COLLEGE   (United States)

^e PRINCESS MARGARET HOSPITAL   (Canada)

^f MCGILL UNIVERSITY   (Canada)

^g SARAH CANNON RESEARCH INSTITUTE   (United States)

^h Peachtree Hematology Oncology Consultants ^*  (United States)

ⁱ Southern Cancer Center   (United States)

^j M D ANDERSON CANCER CENTER ORLANDO   (United States)

^k UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^l DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^m MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

ⁿ EARLE A CHILES RESEARCH INSTITUTE   (United States)

^o Oncology Hematology Consultants   (United States)

^p OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^q JURAVINSKI CANCER CENTRE   (Canada)

^r BAYER CORPORATION   (United States)

^s TAUSSIG CANCER INSTITUTE   (United States)

more..

Author keywords

Bevacizumab; Brain metastases; Expanded access program; First line; Nonclear cell; Progression free survival; Renal cell carcinoma; Sorafenib

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; INTERLEUKIN 2; PLACEBO; SORAFENIB; SUNITINIB; THALIDOMIDE;

ABDOMINAL PAIN; ADOLESCENT; ADVANCED CANCER; AGED; ALOPECIA; ANOREXIA; ARTICLE; BRAIN HEMORRHAGE; BRAIN METASTASIS; CANADA; CENSORSHIP; CLINICAL TRIAL; CONSTIPATION; CONTROLLED STUDY; DEHYDRATION; DESQUAMATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; DYSPNEA; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; HUMAN TISSUE; HYPERTENSION; HYPOPHOSPHATEMIA; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; NAUSEA; NORTH AMERICA; OPEN STUDY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; POPULATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; SIDE EFFECT; TASTE DISORDER; TREATMENT RESPONSE; UNITED STATES; VOMITING; WEIGHT REDUCTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, RENAL CELL; COMPASSIONATE USE TRIALS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NORTH AMERICA; PROTEIN KINASE INHIBITORS; PYRIDINES;

EID: 77149126422     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24864     Document Type: Article

References (30)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2007;58:71-96.
2. Garcia JA, Rini BI. Recent progress in the management of advanced renal cell carcinoma. CA Cancer J Clin. 2007;57:112-125.
3. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med. 1996;335:865-875.
4. Yagoda A, Petrylak D, Thompson S. Cytotoxic chemotherapy for advanced renal cell carcinoma. Urol Clin North Am. 1993;20:303-321.
5. Escudier B. Advanced renal cell carcinoma: current and emerging management strategies. Drugs. 2007;67:1257-1264.
6. Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J Urol. 2000;163:408-417.
7. Atkins MB, Regan M, McDermott D. Update on the role of interleukin-2 and other cytokines in the treatment of patients with stage IV renal carcinoma. Clin Cancer Res. 2004;10:6342S-6346S.
8. Fyfe G, Fisher RI, Rosenberg SA, et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1995;13:688-696.
9. Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N Engl J Med. 1998;338:1272-1278.
10. Collaborators MRCRC. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet. 1999;353:14-17.
11. Negrier S, Maral J, Drevon M, et al. Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe. Cancer J Sci Am. 2000;6(suppl 1):S93-S98.
12. Yang JC, Sherry RM, Steinberg SM, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol. 2003;21:3127-3132.
13. Rini BI, Small EJ. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol. 2005;23:1028-1043.
14. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64:7099-7109.
15. Chang YS, Adnane J, Trail PA, et al. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol. 2007;59:561-574.
16. Levy J, Pauloski N, Braun D. Analysis of transcription and protein expression changes in the 786-O human renal cell carcinoma tumor xenograft model in response to treatment with the multi-kinase inhibitor sorafenib (BAY 43-9006). Proc Am Assoc Cancer Res. 2006;47:213-214.
17. Moore M, Hirte HW, Siu L, et al. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol. 2005;16: 1688-1694.
18. Strumberg D, Richly H, Hilger RA, et al. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol. 2005;23:965-972.
19. Awada A, Hendlisz A, Gil T, et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/ 7 days off in patients with advanced, refractory solid tumours. Br J Cancer. 2005;92:1855-1861.
20. Clark JW, Eder JP, Ryan D, et al. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res. 2005;11:5472-5480.
21. Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebocontrolled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24:2505-2512.
22. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125-134.
23. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
24. Wu S, Chen JJ, Kudelka A, et al. Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol. 2008;9:117-123.
25. Veronese ML, Mosenkis A, Flaherty KT, et al. Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol. 2006;24:1363-1369.
26. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med. 2005;353:2477-2490.
27. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115-124.
28. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370:2103-2111.
29. Tamaskar I, Garcia JA, Elson P, et al. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J Urol. 2008;179:81-86.
30. Rini BI, Michaelson MD, Rosenberg JE, et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol. 2008;26:3743-3748.